Alterity TherapeuticsASX:ATH +3.08%33 5-Year ROIIC % is 55.00 as of Jun. 2025. GuruFocus rates ASX:ATH with a GF Score™ of 33/100. Among 1,176 Biotechnology companies, Alterity Therapeutics ranks better than 78.32% on this metric.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Alterity Therapeutics's 5-Year ROIIC % for the quarter that ended in Jun. 2025 was 55.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Alterity Therapeutics's 5-Year ROIIC % or its related term are showing as below:
ASX:ATH's 5-Year ROIIC % is ranked better than 78.32% of 1176
companies
in the Biotechnology industry
Industry Median: -10.965
vs ASX:ATH: 55.00
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Alterity Therapeutics 5-Year ROIIC % Related Terms
Alterity Therapeutics 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Alterity Therapeutics's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ATH vs VRTX, REGN, ALNY: 5-Year ROIIC % Comparison
For the Biotechnology subindustry, Alterity Therapeutics's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alterity Therapeutics 5-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Alterity Therapeutics's 5-Year ROIIC % falls into.
Alterity Therapeutics's 5-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( -12.334 (Jun. 2025) - -13.466 (Jun. 2020) )
/
( 2.775 (Jun. 2025) - 0.717 (Jun. 2020) )
=
1.132
/
2.058
=
55.00%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Alterity Therapeutics (ASX:ATH) has a 5-Year ROIIC % of 55.00 as of Jun. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Alterity Therapeutics and its competitors. According to the industry distribution chart, Alterity Therapeutics ranks #255 out of 1176 companies in the Biotechnology industry, placing it in the top 21.7%.
Is Alterity Therapeutics' 5-Year ROIIC % too high?
Alterity Therapeutics' current 5-Year ROIIC % is 55.00. Based on the distribution chart, Alterity Therapeutics ranks #255 out of 1176 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alterity Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' 5-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alterity Therapeutics ranks #255 out of 1176 companies for 5-Year ROIIC %. This places Alterity Therapeutics in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Biotechnology company?
A good 5-Year ROIIC % depends on the Biotechnology industry context. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Alterity Therapeutics and its competitors. Alterity Therapeutics's current 5-Year ROIIC % is 55.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current 5-Year ROIIC % of 55.00. The current 5-Year ROIIC % is 55.00. Alterity Therapeutics' overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current 5-Year ROIIC % is 55.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
33GF Score
Get the complete analysis for ASX:ATH
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ATH has been successfully added to your 
